{"name":"Croma-Pharma GmbH","slug":"croma-pharma-gmbh","ticker":"","exchange":"","domain":"cromapharmagmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Botulinum Toxin A - Open Label","genericName":"Botulinum Toxin A - Open Label","slug":"botulinum-toxin-a-open-label","indication":"Cervical dystonia","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Botulinum toxin A \"Botox Cosmetics\"","genericName":"Botulinum toxin A \"Botox Cosmetics\"","slug":"botulinum-toxin-a-botox-cosmetics","indication":"Temporary improvement of moderate to severe glabellar lines (frown lines between eyebrows) in adults","status":"marketed"}]}],"pipeline":[{"name":"Botulinum Toxin A - Open Label","genericName":"Botulinum Toxin A - Open Label","slug":"botulinum-toxin-a-open-label","phase":"phase_3","mechanism":"Botulinum Toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Chronic migraine","Spasticity"],"catalyst":""},{"name":"Botulinum toxin A \"Botox Cosmetics\"","genericName":"Botulinum toxin A \"Botox Cosmetics\"","slug":"botulinum-toxin-a-botox-cosmetics","phase":"marketed","mechanism":"Botulinum toxin A blocks the release of acetylcholine at the neuromuscular junction, causing temporary paralysis of muscles.","indications":["Temporary improvement of moderate to severe glabellar lines (frown lines between eyebrows) in adults","Temporary improvement of forehead lines and crow's feet (off-label cosmetic use)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNQWVIZXBsS0pwOWhHVzVOWmQxUjRJNWc1MFl0X1dhNjBuQm5JeGJZdjdJRXlDaG9CSEhLVlJvRzU2VmRKazF0NDE2STNiZWljSmlRRHZVMzNmWElZUU5yeDE4R2tBbkg2ekJ1eTFDWG41YnFrUVhUQzZwRXV4TDNqendiajFXSTJmV21lcVpjTkUyNFJzbDBydjY3NTY5WW9ueFBTdE5kQjV6STNvN3JLR202LUlyZw?oc=5","date":"2026-04-08","type":"deal","source":"Business Wire","summary":"Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics - Business Wire","headline":"Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQOFlQaWdkYks4T2hCVDg4cFFqMWNBenBzWW9lM0dOQTJod2hlQVpMU1dBcXQzOVdxYzNkMFlrdnVEM3hPWUxYRDEzakhJdWQ2Qmw2VGdwUy1tbG5VWUxqZll1M3RfS1BOYVRtZ1AwOFgxdURWY2ZCYUdBUFJzSVd3ZWNRaGlVVHFwVWlpT2lqd25LcENRMV9rLVVLdjBicVktR09xbEt5WUIydURPc3o2Y1NzNWZDUVR6bldvSFdsbzQ4c0NuSENEa0daYVdXdy1mV3lLdTh4ZEVVSFVBdzBFV3NB?oc=5","date":"2025-12-18","type":"pipeline","source":"Business Wire","summary":"Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF - Business Wire","headline":"Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQb0ZkcUxsbHU0NEoybldyZDVZU2lKN3ExOUdiVk5tLWx1czN2b1Y2X0gxdkExQU8yTkV3ajZZa2ZIbnAyd3M2dmI0cWRaTW4yWXRiU3pIcTF1YXBkMFMyOE5Ob1RWUEpDdWxBdG81WXNfYmg5NElrMS1PUFM3TUw1NjRUTVFkcFh4RnZINTM0N3hjdUVpeVR0UUZRampHZzkzT2N4VFRHdk1FWWw3SjFzQVZwMVYtNlB6QzZCdVlmdUJBZVVmS3ZEZFFmN0ljVjlZLWFSd0RjTHE?oc=5","date":"2025-10-10","type":"deal","source":"PR Newswire","summary":"Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada - PR Newswire","headline":"Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxORmVhaDhTazNjUnJ3MTA3WVdpekROanQtVE8xcXFTeFdIWjRHV0s1OEY4NmQ1YzFIck0zZzVLT3cwZ0NzbXBxc21ZX241dTU3NlZNdlJVUXpQWi15YzJqUnZzM2NnYlV3QjBKaXhQTXZ4U1VjdFlFTjMwaVZvUXYxanhqaGdKenMwbmxqRkFxMnc0bXI0dkFQeENDbmdCVVlteEJ3YmZsUE41SmhjdTg4SENDTHpHZEM1WTlMZ01fMEcwYlJVVXpRNG5rTUdhNGFDclE?oc=5","date":"2025-09-10","type":"regulatory","source":"PA Media","summary":"Croma-Pharma GmbH Celebrates FDA Approval of Obagi saypha® MagIQ™ in the United States - PA Media","headline":"Croma-Pharma GmbH Celebrates FDA Approval of Obagi saypha® MagIQ™ in the United States","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQTkdfdFVXMGwtOGRnWXozdjhPUWNTU1hZSDR2bmxqRHlDcDBJZWJwQ2RrSTJZaFYwOWMzeXFJY2hQNURJMk4tTEh4XzYwV2FROGg0V3c3d0t0NGJ1dDh4UjRpbmpPNG9YdjItMmliejR6RDZOOFRpMFduSGF5ckpFcG82NG80c0lGeWNyOG84anVMMVZkN2hTUml1WnpTVHVQOHk2Y19QR01PY1UzcjJiek16N0RVR2xTdnQwQ2ZxQmp0X0RKZFF0b0dNWV8zakpPUGJsb3RiM1J2TUIxX3BCQllwaFo?oc=5","date":"2025-07-23","type":"deal","source":"marketscreener.com","summary":"Waldencast plc acquired Novaestiq Corp. from Nvq Investors Holding, Llc and CROMA-PHARMA GmbH for $26.9 million. - marketscreener.com","headline":"Waldencast plc acquired Novaestiq Corp. from Nvq Investors Holding, Llc and CROMA-PHARMA GmbH for $26.9 million.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOS0dsOEk3MFRqSVR6NVlydzFJcmhYREttZWNqWFN1dmVNRS15eWtyblYzNmlDYnp5LWpaX1AzOEFMRERYQUxYV0FtMi1YSHgtVzdxTTI4Z3QtdE9FSWFzQW4xT2lZcC1YdkR5d2Q0cExhWk5QWkRMbFhuSWhWaGdpbmlTUDBseW4xOUpCd0hPTmRTbGtFUnhodjJfcDVzUU5sdm5teWJTR0MzMUZOX2FWLWZlUXoydHZnNU5NYkVuSlVLSGJsZ1JrYkhCaG5FY3BjbS1kdGtTY19wSG0zblpIekF1QQ?oc=5","date":"2025-05-23","type":"pipeline","source":"BioSpace","summary":"Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis - BioSpace","headline":"Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOdmswbV8xZnpIY01TbHpPSG9VVzdfeHltNzBsQVN3U1E0UFJyS3lpV1dTU3dYTFFlUU1GRmdIUXZCWDhXVDlVUm1IVFhWQUFodEdaaDg2LWRtbXk3NlpreVUtblRYa1hVZV95UUVQNERNMVJXeERDNHZJWllhSkQ4eXBzZ25qak8wdWtlUlVCbGd3SWhSZjZiTms0cDk0TFVMMm94ejk0TVgwWGhQYkVkVlZUX0xqRXF6cURHcjVDUjhveHdpVVgxZjF3ekp3OS14ZmFPYy1WdEFjamN2RGFOSUJMa2tfWnpqQXF6eWxqX0JiVkJ2dmtwMVpqaVpyemVOX0NnOXZCXzBhRm5V?oc=5","date":"2024-03-28","type":"deal","source":"PR Newswire","summary":"Aesthetic Management Partners Announces Partnership with Croma-pharma To Distribute Plant-Based Exosome Technology to Europe - PR Newswire","headline":"Aesthetic Management Partners Announces Partnership with Croma-pharma To Distribute Plant-Based Exosome Technology to Eu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOTXo5UklwY0gxblljQ0dWTm1hdkVtMkMwYzR0RUktZWcwUVYySjN4Y3ZYWHFnMldUZzhYOFJycU1SdG5iQjBjbVR0NFJrcllMbDVlb0VIZFdITDRWTlM4Y2J2V1BZekhVLThyM2Etd0R5bzdPYkNVR3Z4aHM5M2tzVDVNejlsdjQxVENwRFJMOXVMR1d2QjdiaGlkWVdUdllqLUpuelJXMG0tU2ZxaE40aEl6ai1vQQ?oc=5","date":"2023-08-08","type":"deal","source":"The SPAC Conference","summary":"European Healthcare Acquisition & Growth, Croma-Pharma Cancel Merger Talks - The SPAC Conference","headline":"European Healthcare Acquisition & Growth, Croma-Pharma Cancel Merger Talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPV0pFdGdaaGxVMktjVjI2VTAxSmFFWW1kLVUxQ2h3ZldNbVVJenpKTDByeVF5SnRqM1FDZHkxdmRNOXFaa2h6bXVoX2hfQ3FFN3Z1VzBCYkZuT3JkdXo0N0t6bFV3dUN0dUlpVmlnTG8xNVNvUnpza25VQktUZ3ZpRTdrX2Z5MjhMSlFSNEdFM0Q2WmRzZGFQUHZjUE5QMmprLUQzTEtuS3ZKMUhWVUJwelRTRGFteDRyVE13MEYtV01jb1hEcVgyd3pMeDVVdlRzWlhjVWUzMWVYLWxIZFBscngxNi1lejY2dHdNNXRINFFoRW02QXc?oc=5","date":"2023-06-12","type":"trial","source":"PR Newswire","summary":"Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China - PR Newswire","headline":"Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNQ3Azb2V2a1UyRHdMUXJkY01Eb3AwbWU2VHUtblQwR2hQLXdsbkZhRWJFQVlQZWFGc1FQcUVLZk1oYUN4WU5iOUZWVF8wVHI0YjBVV01BWU15dmFDdTNySXJFX3pfRnJQSGhIRUpzcl83cnk1U1llaVR5VGtRRHJ1TTNreG5pS0hnMzltNkp2UUJISEdDNV9nemFMWHBqQmdxbVBSaVhWVE4wOEp3WDYtMWJjMFVjMGgwbG53WjBCUnRxMVlRY19kRXM5Z3FaZ0Y1SF95MnhhNFBZREQ2dkE?oc=5","date":"2023-05-11","type":"pipeline","source":"PR Newswire","summary":"Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets - PR Newswire","headline":"Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNUmNoTWs3VURzNW1kMklBS2JhMTAwdGtKZTNoWjVnbUhKM0JNc3RjQVUyMXQzTkQyNVJ4SmNMRE5zQTlBcE5WeWlOZXhsN0d1a1lNYzdmSV9JZHBnWGtjZWJvZDM1S3g1Y1NBT0JpVHdWQ0l4ekh5Tk55MEgwbHREQXdYTG9oMkZaU1dTQWp2WXBWVkVaNE9uMDhaMGgzVTRDeFo0?oc=5","date":"2020-09-15","type":"pipeline","source":"Business Wire","summary":"Croma Establishes New Joint Venture in China - Business Wire","headline":"Croma Establishes New Joint Venture in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNazlrdVQwZF8zSkYtajhiTVU5TGFtdUFTMUVlX29YZXZSYjFSOHRJRmdEVkJxVkw1S3ktTzNzU2ttMHF1Yk5XSjZPX01hblNtSVV6U1R0dDFiMG1hUF9EcUZKSzFxcDczSGdmcEg2b2ZQX2dESjRWdW52WlFDQVA1N1I3cUdjZlZjc3g1QTRmbVRqdXM1RTlXUkc2VDl5R1FzRF9NNnhfRW1WWGxDaXQ2TWZvV2w5YjA?oc=5","date":"2020-07-15","type":"pipeline","source":"Business Wire","summary":"Croma-Pharma GmbH expands its portfolio introducing pure HA - Business Wire","headline":"Croma-Pharma GmbH expands its portfolio introducing pure HA","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}